Skip to main
OSTX

OSTX Stock Forecast & Price Target

OSTX Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

OS Therapies is a clinical-stage biopharmaceutical company with a positive outlook due to its potential in addressing the unmet need for new treatments in pediatric and young adult osteosarcoma. Its pipeline of product candidates targeting multiple indications for solid cancers, including the lead drug OST-HER2, has promising clinical data and notable regulatory designations. With potential global regulatory alignment, a strong clinical development plan, and potential market entry in 2026, the company presents as an attractive investment opportunity.

Bears say

OS Therapies is a clinical-stage biopharmaceutical company with a focus on developing treatments for Osteosarcoma (OS) and other solid tumors. While the company has promising pipeline candidates and has received regulatory validation with the initiation of a rolling review for OST-HER2 in Europe, its heavy cost structure and need for continued financing raise concerns about its ability to execute on upcoming milestones. Ultimately, the company's success will depend on its ability to translate positive Phase 2b and biomarker data into a viable accelerated approval path.

OSTX has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OS Therapies Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OS Therapies Inc (OSTX) Forecast

Analysts have given OSTX a Strong Buy based on their latest research and market trends.

According to 2 analysts, OSTX has a Strong Buy consensus rating as of Jun 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OS Therapies Inc (OSTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.